trending Market Intelligence /marketintelligence/en/news-insights/trending/6b469xeQN5RvePtkD7KN6w2 content esgSubNav
In This List

Aurobindo recalls incorrectly labeled cholesterol drugs in US

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Aurobindo recalls incorrectly labeled cholesterol drugs in US

Aurobindo Pharma Ltd. is voluntarily recalling 2,352 bottles of statin tablets due to incorrect labeling, the U.S. Food and Drug Administration said in an enforcement report.

The simvastatin tablets, recalled beginning July 29 after they were labeled with the incorrect lot number, treat high cholesterol and triglyceride levels. The product had already been distributed across the U.S. by three major distributors, according to the report.

The statin drug recall is the latest in a string of Aurobindo's product issues.

Aurobindo previously recalled 80 lots of a separate class of drugs as part of an industrywide recall of the high blood pressure medicines containing sartan, found to be contaminated with cancer-causing impurities.

India-based Aurobindo also faced the ire of the FDA when inspections of its Indian manufacturing facilities caused the regulatory agency to flag several manufacturing and operations concerns. The FDA said in its warning letters that Aurobindo failed to follow the appropriate manufacturing qualities required for finished drug products to meet certain standards of quality and purity.